CMS advises biotech company Immatics Biotechnologies on merger with Arya Sciences Acquisition Corp.

Munich – Immatics Biotechnologies GmbH, which is based in Tübingen, Munich and Houston/Texas, has announced a merger with Arya Sciences Acquisition Corp. Once completed, the merger will make new funds of up to USD 252 million available to the company, which specialises in cancer immunotherapies. Shares in the new holding company, Immatics N.V., will be listed on the New York NASDAQ after the transaction has completed. Completion of the merger is expected in the second quarter of 2020.

An international CMS team headed by lead partners Stefan-Ulrich Müller and Dr Tilman Weichert supported Immatics on all legal aspects of the transaction in Germany and the Netherlands. Immatics regularly relies on the expertise of CMS, with the law firm having advised the company for more than ten years in all financing matters. It has in particular provided legal support for the various venture capital financing rounds. On the American side, the company was advised by Goodwin Procter.

Immatics Biotechnologies GmbH, which is based in Tübingen, Munich and Houston/Texas, is a biopharmaceutical company with a focus on developing cancer immunotherapies using T cells.

Arya Sciences Acquisition Corp. is a blank cheque company formed to carry out a merger, share swap, acquisition of assets, purchase of shares, reorganisation or similar amalgamation with one or more companies or entities.

CMS Germany

Stefan-Ulrich Müller, Lead Partner
Dr Tilman Weichert, Lead Partner
Felix Schmitt, Associate, all Corporate/M&A
Jörg Schrade, Partner
Isabella Denninger, Senior Associate
Finn Fechner, Associate, all Tax
Dr Benedikt Forschner, Senior Associate, Labor, Employment & Pensions

CMS Netherlands

Martijn van der Bie, Partner
Clair Wermers, Counsel, both Corporate/M&A

Press Contact
presse@cms-hs.com